Press Room

Check Out the Latest News and Activities at Proteocyte.

Press Releases

Proteocyte AI featured in online publication 360Dx

Toronto, ON; March 29, 2018 - Proteocyte Diagnostics, a computational pathology company that has built a platform-based technology that predicts your risk of developing cancer, was recently featured in 360Dx. 360Dx covers emerging economic and technological trends in the clinical diagnostic...

read more

Today Proteocyte Diagnostics becomes…

Toronto, ON; March 9, 2018 - Proteocyte Diagnostics, a computational pathology company that has built a platform-based technology that predicts your risk of developing cancer, announced a name change to Proteocyte AI, effectively immediately. “Our new corporate identity better reflects how we...

read more

New Study Shows Straticyte™ More Accurate Than Dysplasia Grading

Toronto, ON; February 2, 2017 - A newly published study shows Straticyte better defines the risk for developing oral squamous cell carcinoma than histopathological dysplasia grading alone. The study “Individualized Five-Year Risk Assessment for Oral Pre-malignant Progression to Cancer”was just...

read more

Select Presentations

1. Hwang, Jason TK et al., A novel prognostic assessment for identifying oral pre-malignant lesions at high risk for progression to cancer. September 18-23, 2016. AAOMS Annual Meeting, Las Vegas, NV, USA

2. Ralhan, R et al. Early detection of oral lesions with dysplasia at high risk of cancer development using a proteomic signature image analysis based Straticyte test. Mar. 4 – 6, 2016. The Global Oral Cancer Forum, NY, USA.

3. Ralhan, R et al. A proteomic signature image analysis based test for predicting risk of cancer development in oral lesions with dysplasia. Feb. 26 – 28, 2016. Tata Memorial Centre Platinum Jubilee – A Conference of new ideas in Cancer. Mumbai, India.

4. Ralhan, R et al. Predicting risk of cancer development in oral lesions with dysplasia using Straticyte. Feb. 23 – Mar. 2, 2016. MedTech Mission to India: MolQ Diagnostics (Guragon); Sapien Biosciences (Hyderabad); Tata Memorial Hospital (Mumbai); ONCQuest Lab and All India Institute of Medical Sciences (New Delhi); Institute of Cytology and Preventive Oncology (Noida).

5. Ralhan, R et al. Prognostic significance of head and neck cancer biomarkers: translation into oral surgery clinics. Sept. 2015. HUPO. Vancouver, Canada.

6. Ralhan, R. Straticyte is an image analysis based prognostic test for oral dysplasia. Jul. 8 – 11, 2015. 5th World IAOO Congress. Sao Paulo, Brazil.

7. Kaur, J et al. Molecular signature for predicting risk of cancer development in oral lesions with dysplasia. Apr. 25 – 30, 2014. Annual Conference of the Academy of Oral and Maxillofacial Pathology. St. Augustine, USA.

8. Ralhan, R. Prognostic markers for oral cancer. Feb. 23, 2012. HNC Translational Research Meeting. UHN, Toronto, Canada.

9. Matta, A et at. Proteomics based prognostic signature of head and neck cancer. May 9 -11, 2011. Canadian National Proteomics Network Symposium. Banff, Canada.

Select Publications

1. Hwang, Jason T.K et al. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. March 2017. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. Vol. 123, Issue 3, Pages 374-381.

2. Chauhan, SS et al. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. 2015. Oncogenesis. doi: 10.1038/oncsis.2015.7

3. Kaur, J et al. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. 2013. Int J Cancer. doi: 10.1002/ijc.28473

4. Tripathi, SC et al. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. 2010. PLoS One. doi: https://dx.doi.org/10.1371/journal.pone.0011939

Sign up, read up, stay informed!

Join our mailing list to stay up-to-date with the latest news and activities from Proteocyte.

Thank you for subscribing to our newsletter!